Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Novo
since
auto-detected in 457 stories
63 days ago
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
64 days ago
Power struggle: will Brazil’s booming datacentre industry leave ordinary people in the dark?
found
a story from The Guardian › International
While millions live with regular blackouts and limited energy, plants are being built to satisfy the global demand for digital storage and processing – piling pressure on an already fragile system
T…
90 days ago
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
found
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
2 months ago
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares gain 4.5% on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares gain 4.5% on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Trump fears drive gold to record high, as yuan hit by US-China trade war – business live
found
a story from The Guardian › International
Rolling coverage of the latest economic and financial news
Novo Nordisk has reported better-than-expected revenues, with sales of its Wegovy obesity drug surging by 86% last year, but expects growth t…
|← first ← previous page 4 of 5 next → last →|